BeOne Medicines Ltd.
BeOne Medicines Ltd. Fundamental Analysis
BeOne Medicines Ltd. (ONC) shows weak financial fundamentals with a PE ratio of 108.10, profit margin of 5.37%, and ROE of 7.28%. The company generates $5.2B in annual revenue with strong year-over-year growth of 54.96%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ONC's fundamental strength across five key dimensions:
Efficiency Score
WeakONC struggles to generate sufficient returns from assets.
Valuation Score
ModerateONC shows balanced valuation metrics.
Growth Score
ExcellentONC delivers strong and consistent growth momentum.
Financial Health Score
ExcellentONC maintains a strong and stable balance sheet.
Profitability Score
WeakONC struggles to sustain strong margins.
Key Financial Metrics
Is ONC Expensive or Cheap?
P/E Ratio
ONC trades at 108.10 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ONC's PEG of 1.68 indicates fair valuation.
Price to Book
The market values BeOne Medicines Ltd. at 7.11 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 44.03 times EBITDA. This signals the market has high growth expectations.
How Well Does ONC Make Money?
Net Profit Margin
For every $100 in sales, BeOne Medicines Ltd. keeps $5.37 as profit after all expenses.
Operating Margin
Core operations generate 8.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.28 in profit for every $100 of shareholder equity.
ROA
BeOne Medicines Ltd. generates $3.50 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BeOne Medicines Ltd. produces operating cash flow of $1.10B, showing steady but balanced cash generation.
Free Cash Flow
BeOne Medicines Ltd. generates strong free cash flow of $600.80M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.62 in free cash annually.
FCF Yield
ONC converts 2.02% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
108.10
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.68
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.11
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.69
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.46
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.41
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How ONC Stacks Against Its Sector Peers
| Metric | ONC Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 108.10 | 28.25 | Worse (Expensive) |
| ROE | 7.28% | 780.00% | Weak |
| Net Margin | 5.37% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.46 | 0.30 | Weak (High Leverage) |
| Current Ratio | 3.41 | 4.66 | Strong Liquidity |
| ROA | 3.50% | -14687.00% (disorted) | Weak |
ONC outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BeOne Medicines Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
407.52%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
61.23%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
89.31%
Industry Style: Defensive, Growth, Innovation
High Growth